Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003384 · ClinicalTrials.gov registry record · NA
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer
A NA study of Precancerous Condition and Stage 0 Cervical Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- NA
- Development phase
- 684
- Enrollment target
- 1
- Study location
NCT00003384 is a NA study of Precancerous Condition and Stage 0 Cervical Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 684 participants, above the 577-participant average among 15 other Precancerous Condition trials with a reported enrollment target (19% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00003384, a NA study of Precancerous Condition and Stage 0 Cervical Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- NA
- Development phase
- 684 participants
- Enrollment target
- 1
- Study location
Study Summary
This diagnostic trial is studying the presence of a specific protein as a potential biomarker of cervical dysplasia and/or cancer. The presence of specific proteins may allow a doctor to determine whether a patient has cervical dysplasia and/or cancer.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Conization
- OTHER Cervical Papanicolaou Test
Study Locations (1)
Arizona
- Gynecologic Oncology Group of Arizona - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 684 participants |
| Start Date | 1998-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003384
The ClinicalTrials.gov registry entry for NCT00003384 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 684 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 577-participant average among 15 other Precancerous Condition trials with a reported enrollment target (19% higher). The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Precancerous Condition appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00003384 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT00003384 about?
NCT00003384 is a clinical study titled "Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer". This diagnostic trial is studying the presence of a specific protein as a potential biomarker of cervical dysplasia and/or cancer. The presence of specific proteins may allow a doctor to determine whether a patient has cervical dysplasia and/or cancer.
What is the current status of trial NCT00003384?
This trial is currently completed. It is a NA study. The enrollment target is 684 participants. The study started on 1998-09.
What conditions does trial NCT00003384 study?
This clinical trial studies the following conditions: Precancerous Condition, Stage 0 Cervical Cancer.
What interventions are being tested in trial NCT00003384?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Conization (PROCEDURE), Cervical Papanicolaou Test (OTHER).
Who is sponsoring clinical trial NCT00003384?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003384 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Precancerous Condition
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia
COMPLETED · NA
-
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
RECRUITING
-
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
RECRUITING
-
Lovastatin in Treating Patients At High Risk of Melanoma
COMPLETED · Phase 2
-
Biomarkers in the Nose, Throat, and Lung Tissue of Smokers and Non-Smokers
COMPLETED
-
Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.